What happens when you stop taking Mounjaro

What the trial data actually showed when tirzepatide was stopped

The SURMOUNT-1 trial (published in the New England Journal of Medicine) randomised over 2,500 adults with obesity and tracked outcomes at 72 weeks. Participants on 15 mg tirzepatide lost around 20–21% of body weight on average. A separate extension phase then withdrew active treatment, and the pattern seen there mirrors what has been observed across GLP-1 research more broadly: a meaningful proportion of lost weight returned over the following months.

This is not a failure of the medicine or the person. Obesity is a chronic condition shaped by hormones, genetics and environment; tirzepatide works by modulating two gut-hormone receptors involved in appetite signalling. Once those signals are no longer being modulated, the body's prior set-point reasserts itself. The NHS tirzepatide patient information reinforces that this medicine works alongside, not instead of, long-term lifestyle changes.

The practical implication is that stopping is a genuine clinical event, not simply an administrative one. It deserves the same prescriber conversation as starting.

What actually happens to your appetite and weight after your last pen

Tirzepatide's half-life is approximately five days. That means the medicine is substantially cleared from the body within two to three weeks of the last injection. During that window, most people notice hunger returning, sometimes gradually, sometimes quite sharply. Gastric emptying speeds back up, satiety signals weaken, and food can feel appealing in a way it hadn't for months.

If you have been tracking your progress, it is worth knowing that the scale can move quickly in the first few weeks after stopping, partly because food volume and fluid retention normalise. This is not the same as fat regain, though fat regain can follow if energy intake rises without compensating activity. If you find yourself in a position where you have stopped losing weight on Mounjaro, it is worth understanding the mechanisms behind that before deciding whether to continue or stop altogether.

There is no physical withdrawal syndrome in the pharmacological sense. But the psychological shift can feel significant. If you relied on reduced appetite to manage portion sizes, its return can be disorienting. That is worth saying plainly, because many people are caught off guard by how different eating feels once tirzepatide is out of their system.

Common reasons people stop, and what the evidence suggests for each

Side effects are the most frequently cited reason for stopping early, particularly nausea, vomiting and digestive discomfort during the titration phase. Clinical guidance consistently recommends slower titration as a first response rather than stopping altogether; our Mounjaro overview covers how the dosing schedule works and why that matters. A prescriber reviewing your case may be able to adjust rather than discontinue.

Cost is another common factor. The market price of tirzepatide in the UK has shifted considerably since Eli Lilly revised its list price in late 2025, and it is worth understanding what a full private treatment package includes before assuming stopping is the only option. Sometimes people stop without realising that aftercare support (the very thing designed to help through difficult patches) is available to them.

Some people stop because they feel they have reached their goal. That is understandable. The evidence on sustained weight maintenance without continued treatment is not optimistic for most people, but individual outcomes vary. If this is your situation, an honest conversation with a prescriber about planned cessation, monitoring weight and what to look for is more useful than an abrupt stop with no follow-up plan.

There is also the question of what happens if Mounjaro simply stops working as well as it once did. If that is your experience, you can read about what to do when weight loss has stopped on Mounjaro before making a decision, and it is also worth reading about why Mounjaro's effect can plateau.

Restarting, switching, or planning a clinical pause

Restarting tirzepatide after a gap is possible, but it is not simply a case of picking up where you left off. Prescribers typically recommend restarting at a lower dose to allow the body to readjust, particularly if the gap has been several weeks or longer. The practical guidance on pausing and restarting Mounjaro walks through what that process typically looks like clinically.

For some people, switching to a different licensed weight-management medicine is worth exploring. Wegovy (semaglutide) works through a single GLP-1 pathway rather than tirzepatide's dual GIP and GLP-1 action; the mechanisms differ enough that some individuals who found one difficult tolerate the other better. A prescriber can assess which is appropriate given your history and current health picture. Our clinical team at the prescriber profile page describes how that review works.

If you have questions about injections and hormonal effects (for example, if your periods changed during treatment and you are wondering whether stopping will resolve that) there is specific evidence worth reviewing on how Mounjaro can affect the menstrual cycle.

Every repeat prescription at nume is clinically re-reviewed before it is issued. That same prescriber oversight applies to anyone considering stopping, pausing or restarting. If you want a proper clinical opinion rather than a best guess, speaking to a prescriber is the right move. Start a free consultation to speak to our prescribers about your specific situation.